MRSN vs. LXEO, BIVI, BIOA, VTYX, MOLN, IMRX, THTX, NMRA, ALEC, and LYEL
Should you be buying Mersana Therapeutics stock or one of its competitors? The main competitors of Mersana Therapeutics include Lexeo Therapeutics (LXEO), BioVie (BIVI), BioAge Labs (BIOA), Ventyx Biosciences (VTYX), Molecular Partners (MOLN), Immuneering (IMRX), Theratechnologies (THTX), Neumora Therapeutics (NMRA), Alector (ALEC), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry.
Mersana Therapeutics vs. Its Competitors
Lexeo Therapeutics (NASDAQ:LXEO) and Mersana Therapeutics (NASDAQ:MRSN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.
Mersana Therapeutics has higher revenue and earnings than Lexeo Therapeutics. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks.
Lexeo Therapeutics presently has a consensus target price of $16.60, indicating a potential upside of 271.36%. Mersana Therapeutics has a consensus target price of $5.20, indicating a potential upside of 1,412.07%. Given Mersana Therapeutics' higher possible upside, analysts clearly believe Mersana Therapeutics is more favorable than Lexeo Therapeutics.
In the previous week, Lexeo Therapeutics had 6 more articles in the media than Mersana Therapeutics. MarketBeat recorded 8 mentions for Lexeo Therapeutics and 2 mentions for Mersana Therapeutics. Mersana Therapeutics' average media sentiment score of 0.93 beat Lexeo Therapeutics' score of 0.39 indicating that Mersana Therapeutics is being referred to more favorably in the news media.
60.7% of Lexeo Therapeutics shares are held by institutional investors. Comparatively, 93.9% of Mersana Therapeutics shares are held by institutional investors. 5.3% of Lexeo Therapeutics shares are held by company insiders. Comparatively, 13.0% of Mersana Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Lexeo Therapeutics has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.
Lexeo Therapeutics has a net margin of 0.00% compared to Mersana Therapeutics' net margin of -217.63%. Lexeo Therapeutics' return on equity of -85.86% beat Mersana Therapeutics' return on equity.
Summary
Mersana Therapeutics beats Lexeo Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Mersana Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mersana Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MRSN) was last updated on 7/11/2025 by MarketBeat.com Staff
